

Supplemental Figures

Figure S1. Effect of immune-suppressive therapies on B-cell counts in CGD patients.

CD19⁺ B-cell counts are shown for HD and CGD patients. The CGD group was also divided into two subgroups based on immunosuppressive therapies (Table 1): “no/low dose” for those receiving no treatment or <0.1 mg/kg/day prednisone and/or humira; and “high dose” for those receiving >0.1 mg/kg/day prednisone or methotrexate. Horizontal bars represent medians.

Figure S2. Lower frequencies of CD27-expressing B cells in CGD patients with the

gp91^{phox} mutation. PBMCs of CGD patients were stained with antibodies against CD3, CD10, CD19, CD21 and CD27 for FACS analysis. Gating on CD19⁺/CD3⁻ cells established the B-cell population. Shown are (A) resting and (B) activated memory B cells. Horizontal bars represent medians.

Figure S3. Normal IgG memory B-cell responses in CGD patients.

ASC frequencies shown in Figures 5A and 5B are expressed per B-cell. The percentages of B cells in the PBMC cultures after 4 days were evaluated by immunophenotyping. Horizontal bars represent medians.

Figure S1




Figure S2




Figure S3

